2026-04-29T04:52:21Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/228992024-11-29T04:14:10Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Gonzalez-Freire, Marta
author
Diaz-Ruiz, Alberto
author
Hauser, David
author
Martinez-Romero, Jorge
author
Ferrucci, Luigi
author
Bernier, Michel
author
de Cabo, Rafael
2024-09-13T09:13:26Z
2024-09-13T09:13:26Z
2020-05
Gonzalez-Freire M, Diaz-Ruiz A, Hauser D, Martinez-Romero J, Ferrucci L, Bernier Ml, et al. The road ahead for health and lifespan interventions. Ageing Res Rev. 2020 May;59:101037. Epub 2020 Feb 25.
1568-1637
http://hdl.handle.net/20.500.13003/17245
https://hdl.handle.net/20.500.12105/22899
32109604
10.1016/j.arr.2020.101037
1872-9649
Ageing Research Reviews
2-s2.0-85080096327
525863700004
L2005097568
Aging is a modifiable risk factor for most chronic diseases and an inevitable process in humans. The development of pharmacological interventions aimed at delaying or preventing the onset of chronic conditions and other age-related diseases has been at the forefront of the aging field. Preclinical findings have demonstrated that species, sex and strain confer significant heterogeneity on reaching the desired health- and lifespan-promoting pharmacological responses in model organisms. Translating the safety and efficacy of these interventions to humans and the lack of reliable biomarkers that serve as predictors of health outcomes remain a challenge. Here, we will survey current pharmacological interventions that promote lifespan extension and/or increased healthspan in animals and humans, and review the various anti-aging interventions selected for inclusion in the NIA's Interventions Testing Program as well as the ClinicalTrials.gov database that target aging or age-related diseases in humans.
eng
Lifespan
Healthspan
Aging
anti-aging
Longevity
Frailty
Translation
The road ahead for health and lifespan interventions
review article